Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls

Schizophrenia Bulletin

Volumn 40, Issue 3, 2014, Pages 592-601

  Zhang, Xiang Y ^a,b   Chen, Da C ^b   Xiu, Mei H ^b   Yang, Fu D ^b   Tan, Yunlong ^b   Luo, Xingguang ^c   Zuo, Lingjun ^c   Kosten, Therese A ^a   Kosten, Thomas R ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PEKING UNIVERSITY   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

association; cognition; genotype; manganese superoxide dismutase; polymorphism; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; MANGANESE SUPEROXIDE DISMUTASE; NEUROLEPTIC AGENT; PERPHENAZINE; QUETIAPINE; REACTIVE OXYGEN METABOLITE; RISPERIDONE; SULPIRIDE; SUPEROXIDE DISMUTASE;

ADULT; ALLELE; ARTICLE; ATTENTION DISTURBANCE; BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; PSYCHOLOGY;

ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPEROXIDE DISMUTASE;

EID: 84899018227     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt045     Document Type: Article

References (67)

1. Kremen WS, Seidman LJ, Faraone SV, Tsuang MT. Intelligence quotient and neuropsychological profiles in patients with schizophrenia and in normal volunteers. Biol Psychiatry. 2001;50:453-462.
2. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology. 1998;12:426-445.
3. Harvey PD, Green MF, Keefe RS, Velligan DI. Cognitive functioning in schizophrenia: A consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry. 2004;65:361-372.
4. Goff DC, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav. 2011;99:245-253.
5. Niendam TA, Bearden CE, Rosso IM, et al. A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. Am J Psychiatry. 2003;160:2060-2062.
6. Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev. 2009;19:324-335.
7. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58:24-32.
8. Rajji TK, Mulsant BH. Nature and course of cognitive function in late-life schizophrenia: A systematic review. Schizophr Res. 2008;102:122-140.
9. Irani F, Kalkstein S, Moberg EA, Moberg PJ. Neuropsychological performance in older patients with schizophrenia: A meta-Analysis of cross-sectional and longitudinal studies. Schizophr Bull. 2011;37:1318-1326.
10. Lewis DA, Lieberman JA. Catching up on schizophrenia: Natural history and neurobiology. Neuron. 2000;28:325-334.
11. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301-307.
12. Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry. 2008;7:22-28.
13. Galletly C. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl). 2009;202:259-273.
14. Barch DM. Pharmacological strategies for enhancing cognition in schizophrenia. Curr Top Behav Neurosci. 2010;4:43-96.
15. Lohr JB. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen Psychiatry. 1991;48:1097-1106.
16. Lohr JB, Browning JA. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull. 1995;31:159-165.
17. Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res. 2003;62:205-212.
18. Reddy RD, Yao JK. Free radical pathology in schizophrenia: A review. Prostaglandins Leukot Essent Fatty Acids. 1996;55:33-43.
19. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: An overview of the evidence and its therapeutic implications. CNS Drugs. 2001;15:287-310.
20. Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 1996;55:45-54.
21. Halliwell B. Reactive oxygen species in living systems: Source, biochemistry, and role in human disease. Am J Med. 1991;91:14S-22S.
22. Reddy R, Sahebarao MP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry. 1991;30:409-412.
23. Yao JK, Reddy R, McElhinny LG, van Kammen DP. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res. 1998;32:385-391.
24. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: Association with positive symptoms. Psychiatry Res. 2003;117:85-88.
25. Mukerjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res. 1996;19:19-26.
26. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol. 2003;15:247-254.
27. Guidot DM, McCord JM, Wright RM, Repine JE. Absence of electron transport (Rho 0 state) restores growth of a manganese-superoxide dismutase-deficient Saccharomyces cerevisiae in hyperoxia. Evidence for electron transport as a major source of superoxide generation in vivo. J Biol Chem. 1993;268:26699- 26703.
28. Robinson BH. The role of manganese superoxide dismutase in health and disease. J Inherit Metab Dis. 1998;21:598-603.
29. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun. 1996;226:561-565.
30. Michel TM, Thome J, Martin D, et al. Cu, Zn-And Mnsuperoxide dismutase levels in brains of patients with schizophrenic psychosis. J Neural Transm. 2004;111:1191-1201.
31. Lindholm E, Ekholm B, Shaw S, et al. A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. Am J Hum Genet. 2001;69:96-105.
32. Shimoda-Matsubayashi S, Hattori T, Matsumine H, et al. Mn SOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control. Neurology. 1997;49:1257-1262.
33. Hori H, Ohmori O, Shinkai T, et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: Relation to tardive dyskinesia. Neuropsychopharmacology. 2000;23:170-177.
34. Akyol O, Yanik M, Elyas H, et al. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:123-131.
35. Zhang Z, Zhang X, Hou G, Sha W, Reynolds GP. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res. 2002;36:317-324.
36. Ventriglia M, Scassellati C, Bonvicini C, et al. No association between Ala9Val functional polymorphism of MnSOD gene and schizophrenia in a representative Italian sample. Neurosci Lett. 2006;410:208-211.
37. Hitzeroth A, Niehaus DJ, Koen L, Botes WC, Deleuze JF, Warnich L. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:664-672.
38. Pae CU, Kim TS, Patkar AA, et al. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia. Psychiatry Res. 2007;153:77-81.
39. Galecki P, Pietras T, Szemraj J. [Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland]. Psychiatr Pol. 2006;40:937-948.
40. Thelma BK, Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: Role of oxidative stress pathway genes. Schizophr Res. 2007;92:278-279.
41. Kang SG, Choi JE, An H, et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1844-1847.
42. Pae CU. Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia. Psychiatry Res. 2008;161:336-338.
43. Zai CC, Tiwari AK, Basile V, et al. Oxidative stress in tardive dyskinesia: Genetic association study and meta-Analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:50-56.
44. Liu H, Wang C, Chen PH, et al. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:692-696.
45. Nicolle MM, Gonzalez J, Sugaya K, et al. Signatures of hippocampal oxidative stress in aged spatial learning-impaired rodents. Neuroscience. 2001;107:415-431.
46. Hu D, Xu X, Gonzalez-Lima F. Vicarious trial-And-error behavior and hippocampal cytochrome oxidase activity during Y-maze discrimination learning in the rat. Int J Neurosci. 2006;116:265-280.
47. Hu D, Cao P, Thiels E, et al. Hippocampal long-Term potentiation, memory, and longevity in mice that overexpress mitochondrial superoxide dismutase. Neurobiol Learn Mem. 2007;87:372-384.
48. Serrano F, Klann E. Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res Rev. 2004;3:431-443.
49. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310-319.
50. Zhang BH, Zhang WF, Wang ZR. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) as a screening test in Chinese: Reliability and validity. Chin Ment Health J. 2009;28:865-869.
51. Zhang XY, Tan YL, Cao LY, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res. 2006;81:291-300.
52. Zhang B, Tan Z, Zhang C, et al. Polymorphisms of chromogranin B gene associated with schizophrenia in Chinese Han population. Neurosci Lett. 2002;323:229-233.
53. Dickerson F, Boronow JJ, Stallings C, Origoni AE, Cole SK, Yolken RH. Cognitive functioning in schizophrenia and bipolar disorder: Comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status. Psychiatry Res. 2004;129:45-53.
54. Goldberg TE, Egan MF, Gscheidle T, et al. Executive subprocesses in working memory: Relationship to catechol-Omethyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry. 2003;60:889-896.
55. Egan MF, Straub RE, Goldberg TE, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA. 2004;101: 12604-12609.
56. Ranjekar PK, Hinge A, Hegde MV, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003;121:109-122.
57. Khan NS, Das I. Oxidative stress and superoxide dismutase in schizophrenia. Biochem Soc Trans. 1997;25:418S.
58. Sánchez-Rodríguez MA, Santiago E, Arronte-Rosales A, Vargas-Guadarrama LA, Mendoza-Núnez VM. Relationship between oxidative stress and cognitive impairment in the elderly of rural vs. urban communities. Life Sci. 2006;78: 1682-1687.
59. Mendoza-Nunez VM, Retana-Ugalde R, Sánchez-Rodríguez MA, Altamirano-Lozano MA. DNA damage in lymphocytes of elderly patients in relation with total antioxidant levels. Mech Ageing Dev. 1999;108:9-23.
60. Mendoza-Núnez VM, Sánchez-Rodríguez MA, Retana-Ugalde R, Vargas-Guadarrama LA, Altamirano-Lozano MA. Total antioxidant levels, gender, and age as risk factors for DNA damage in lymphocytes of the elderly. Mech Ageing Dev. 2001;122:835-847.
61. Pagano G, Castello G. Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv Exp Med Biol. 2012;724:291-299.
62. Gulesserian T, Seidl R, Hardmeier R, Cairns N, Lubec G. Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med. 2001;49:41-46.
63. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17:47-62.
64. Yao JK, Reddy R. Oxidative stress in schizophrenia: Pathogenetic and therapeutic implications. Antioxid Redox Signal. 2011;15:1999-2002.
65. Duff K, Patton D, Schoenberg MR, Mold J, Scott JG, Adams RL. Age-And education-corrected independent normative data for the RBANS in a community dwelling elderly sample. Clin Neuropsychol. 2003;17:351-366.
66. Beatty WW, Mold JW, Gontkovsky ST. RBANS performance: Influences of sex and education. J Clin Exp Neuropsychol. 2003;25:1065-1069.
67. Cheng Y, Wu W, Wang J, Feng W, Wu X, Li C. Reliability and validity of the Repeatable Battery for the Assessment of Neuropsychological Status in community-dwelling elderly. Arch Med Sci. 2011;7:850-857.